Peptilotbeta
← All papers
πŸ§ͺ Registered trialInsufficientinterventionalOpen access

Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function

Helsinn Therapeutics (U.S.), Inc
ClinicalTrials.gov Β· January 20, 2011
Plain-language summary

Registered Phase 2 interventional trial (completed). Post-operative administration of ipamorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial small and/or large bowel resection.

Ask the literature about ipamorelin β†’
Trial record

Registered clinical trial record on ClinicalTrials.gov (NCT01280344). This describes a planned, ongoing, or completed study β€” it is NOT peer-reviewed results. Status: completed. Study type: interventional. Phase: Phase 2. Sponsor: Helsinn Therapeutics (U.S.), Inc. Conditions: Gastrointestinal Dysmotility. Interventions: Saline Solution for Injection, Ipamorelin. Summary: Post-operative administration of ipamorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial small and/or large bowel resection. Primary outcome measures: Recovery of Gastrointestinal (GI) Function. Eligibility: Inclusion Criteria: * Able to freely give written informed consent to participate in the study and have signed the Informed Consent Form * Males or females, 18 to 85 years of age inclusive at the time of study screening * American Society of Anesthesiologists (ASA) Class I-III * Have undergone a scheduled small and/or large open partial bowel resection based on a documented incision size greater than or equal to (β‰₯) 10 cm with primary anastomosis * Females must not be pregnant as confirmed by a serum pregnancy test at screening and by a urine pregnancy test on the day of surgery * Body weight must be between 40-150 kilograms (kg) Exclusion Criteria: * Any procedure which requires a diverting stoma * Primary anastomosis not performed at the time of surgery * Epidural or intrathecal anesthesia * Significant liver disease (ALT and/or total bilirubin \> 2-fold upper limits of normal) or kidney disease (serum creatinine \> 2.5 mg/dL) at screening * History of irritable bowel syndrome * Patients with a history of Crohn's disease or ulcerative colitis (UC) who have had multiple GI-related surgeries (Note: surgery naΓ―ve Crohn's or UC patients may be included) * History of colonic volvulus * History of gastroesophageal surgery, gastrectomy, gastric bypass, total colectomy, short bowel syndrome, or multiple complex abdominal surgeries performed by an open procedure (uncomplicated cesarean section and appendectomy would not be considered complex) * Patients who have received prior abdominal radiation and/or pelvic radiation

This is a registered clinical-trial record from ClinicalTrials.gov β€” a description of a planned, ongoing, or completed study, not peer-reviewed results. Listing on ClinicalTrials.gov does not mean the study has been evaluated by the U.S. Federal Government, nor does it imply endorsement or that the intervention is safe or effective.

Educational summary of published research β€” not medical advice. License: public-domain. Full text is shown only where licensing permits.